Rani Therapeutics Holdings, Inc. (NasdaqGM: RANI)
Health Care · Pharmaceuticals · US
$0.84
-5.57% today · +49.3% 1Y
Rani Therapeutics Holdings, Inc. (NasdaqGM: RANI) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $97.12M and employs 70 people.
Over the last twelve months the share price has gained 49.3%, trading between 0.44 and 3.87.
Tweenvest scores Rani Therapeutics Holdings, Inc. across four factors: quality 28/100, value 63/100. Its strongest factor is value.
RANI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $97.12M
- Revenue (TTM)
- $4.88M
- P/E
- —
- EPS
- -0.22
- Dividend yield
- —
- Beta (5Y)
- 0.70
- 52-week high
- $3.87
- 52-week low
- $0.44
- Avg volume (3M)
- —
- Shares outstanding
- 115.42M
- Employees
- 70
- Next earnings
- —
About Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
- ISIN
- US7530181004
- Founded
- 2012
- Listed since
- Jul 30, 2021
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.06T | $1,189.41 | -3.59% |
| Johnson & JohnsonNYSE: JNJ | $650.67B | $270.00 | -1.15% |
| Merck & Co., Inc.NYSE: MRK | $377.72B | $153.10 | -2.14% |
| Roche Holding AGSWX: ROP | $365.10B | CHF368.30 | -1.47% |
| Novartis AGSWX: NOVN | $300.07B | CHF127.18 | -0.90% |
| AstraZeneca PLCLSE: AZN | $257.89B | £122.34 | -1.94% |
| Novo Nordisk A/SCPSE: NOVO B | $210.23B | Dkr304.95 | -0.93% |
| Pfizer Inc.NYSE: PFE | $161.30B | $28.30 | -0.95% |
Figures last refreshed Aug 18, 2026.